Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD) Clinical Trial

Official title:

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02169453
• Other study ID #: BIA-91067-110
• Status: Completed
• Phase: Phase 1
• First received: January 20, 2012
• Last updated: January 14, 2015
• Start date: October 2008
• Est. completion date: January 2009

Study information

• Verified date: January 2015
• Source: Bial - Portela C S.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg (Sinemet® CR 100/25)

Description:

Single centre, double-blind, randomized, placebo-controlled, crossover study with four consecutive single-dose treatment periods. The washout period between doses was to be at least 14 days. On each treatment period, after completion of pre-dose assessments, BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25; post-dose assessments were to be completed and subjects were to be discharged 72 h post-dose. Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Availability for the entire study period and willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer prior to participation in the study.

• Male volunteers.

• Volunteers of at least 18 years of age but not older than 45 years.

• Volunteers with body mass index (BMI) greater than or equal to 19 and below 30 kg/m2.

• Volunteers who were non- or ex-smokers. An ex-smoker is defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.

• Volunteers who were healthy as determined by pre-study (at screening) medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.

• Volunteers who had clinical laboratory test results judged clinically acceptable (within the laboratory's stated normal range; if not within this range, they must had been without any clinical significance) at screening and admission to first treatment period.

• Volunteers who had negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2 antibodies (HIV-1 and HIV-2 Ab) at screening.

• Volunteers who had negative screen of ethyl alcohol and drugs of abuse at screening.

• Due to unknown risks and potential harm to the unborn fetus, sexually active men must have agreed to use a medically acceptable form of contraception throughout the study.

Exclusion Criteria:

• Volunteers who did not conform to the above inclusion criteria, or in case of

• Volunteers who had a clinically relevant surgical history.

• Volunteers who had a clinically relevant family history.

• Volunteers who had a history of relevant atopy.

• Volunteers who had a significant infection or known inflammatory process at screening or first admission.

• Volunteers who had acute gastrointestinal symptoms at the time of screening or first admission (e.g., nausea, vomiting, diarrhoea, heartburn).

• Volunteers who were vegetarians, vegans or have medical dietary restrictions.

• Volunteers who could not communicate reliably with the investigator.

• Volunteers who were unlikely to co-operate with the requirements of the study.

• Significant history of hypersensitivity to BIA 9-1067, tolcapone, entacapone, levodopa, carbidopa or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.

• Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.

• History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability.

• Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, lymphatic, musculoskeletal, genitourinary, endocrine, immunologic, dermatologic or connective tissue disease.

• Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases.

• Presence of significant heart disease or disorder according to ECG.

• Presence of suspicious undiagnosed skin lesions or a history of melanoma.

• Previous history of Neuroleptic Malignant Syndrome (NMS) and/or nontraumatic rhabdomyolysis.

• Presence or history of significant glaucoma.

• Used of prescription medications including monoamine oxidase (MAO) inhibitors within 28 days before day 1 of the study.

• Used of over-the-counter (OTC) products within 7 days before day 1 of the study.

• Maintenance therapy with any drug, or significant history of drug dependency (drug abuse) or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).

• Any clinically significant illness in the previous 28 days before day 1 of this study.

• Used of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampicin), in the previous 28 days before day 1 of this study.

• Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.

• Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately, inability to understand and to observe the instructions of the physician.

• Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.

• Positive urine screening of ethyl alcohol or drugs of abuse at admission to any treatment period.

• Any history of tuberculosis and/or prophylaxis for tuberculosis.

• Positive results to HIV, HBsAg or anti-HCV tests.

• Participation in any previous clinical study with BIA 9-1067 within 84 days before day 1 of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease (PD)

Intervention

Drug:
• BIA 9-1067
OPC, Opicapone
• Placebo
PLC, Placebo
• Sinemet® CR 100/25
Controlled-release levodopa/carbidopa 100/25 mg

Locations

Country	Name	City	State
Canada	Algorithme Pharma Inc	Mount-Royal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Bial - Portela C S.A.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax - Maximum Observed Plasma Concentration	Cmax - Maximum observed plasma concentration of levodopa	pre-dose, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose	No
Primary	AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point	AUC0-t - Area under the plasma concentration-time curve to last measurable time point for levodopa	pre-dose, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose	No
Primary	AUC0-8 - Area Under the Plasma Concentration-time Curve Extrapolated to Infinity	AUC0-8 - Area under the plasma concentration-time curve extrapolated to infinity for levodopa	pre-dose, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose	No
Primary	Emax - Maximum Inhibition of COMT Activity	Emax - Maximum inhibition of Catechol-O-Methyltransferase (COMT) activity	pre-dose, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose	No
Primary	tEmax - Time of Occurrence of Emax		pre-dose, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose	No
Primary	AUEC0-24 - Area Under the Effect-time Curve From t=0h to t=24h		pre-dose, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose	No